MX2015007085A - Composiciones de acido omega-3 pentanoico y metodos de uso. - Google Patents
Composiciones de acido omega-3 pentanoico y metodos de uso.Info
- Publication number
- MX2015007085A MX2015007085A MX2015007085A MX2015007085A MX2015007085A MX 2015007085 A MX2015007085 A MX 2015007085A MX 2015007085 A MX2015007085 A MX 2015007085A MX 2015007085 A MX2015007085 A MX 2015007085A MX 2015007085 A MX2015007085 A MX 2015007085A
- Authority
- MX
- Mexico
- Prior art keywords
- dha
- omega
- fatty acids
- dpa
- epa
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 2
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 2
- 239000006014 omega-3 oil Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 1
- 230000001258 dyslipidemic effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23B20/00—Preservation of edible oils or fats
- A23B20/30—Preservation of other edible oils or fats, e.g. shortenings or cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
- C11B5/0007—Organic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734331P | 2012-12-06 | 2012-12-06 | |
| US201361780948P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/073701 WO2014089501A1 (en) | 2012-12-06 | 2013-12-06 | Omega-3 pentaenoic acid compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015007085A true MX2015007085A (es) | 2016-01-12 |
Family
ID=50884050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007085A MX2015007085A (es) | 2012-12-06 | 2013-12-06 | Composiciones de acido omega-3 pentanoico y metodos de uso. |
| MX2015007082A MX2015007082A (es) | 2012-12-06 | 2013-12-06 | Métodos de administración de composiciones que comprenden ácido docosapentanoico. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007082A MX2015007082A (es) | 2012-12-06 | 2013-12-06 | Métodos de administración de composiciones que comprenden ácido docosapentanoico. |
Country Status (9)
| Country | Link |
|---|---|
| EP (3) | EP2929041A4 (enExample) |
| JP (4) | JP6881893B2 (enExample) |
| KR (3) | KR20150103009A (enExample) |
| CN (4) | CN112107570A (enExample) |
| AU (7) | AU2013354979A1 (enExample) |
| CA (2) | CA2894366A1 (enExample) |
| IN (2) | IN2015MU01505A (enExample) |
| MX (2) | MX2015007085A (enExample) |
| WO (2) | WO2014089501A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101568665B1 (ko) | 2015-07-21 | 2015-11-12 | 디와이오토 주식회사 | 모터의 맥동 전류를 증가시키는 브러시 구조 |
| WO2018001844A1 (en) * | 2016-06-28 | 2018-01-04 | Nestec S.A. | Biomarkers of blood-brain barrier dysfunction |
| JP2018168139A (ja) * | 2016-10-21 | 2018-11-01 | マルハニチロ株式会社 | ｎ−３系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるｎ−３系不飽和脂肪酸の使用 |
| JP7099821B2 (ja) * | 2017-12-20 | 2022-07-12 | ポッカサッポロフード＆ビバレッジ株式会社 | Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物 |
| EP3586643A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| EP3586641A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| EP3586642A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Ala enriched polyunsaturated fatty acid compositions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| JP2002125618A (ja) * | 2000-10-30 | 2002-05-08 | Katsuyuki Wakatsuki | 健康食品 |
| EP1714564A1 (en) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Method for treatment and prevention of respiratory insufficiency |
| WO2007058523A1 (en) | 2005-11-17 | 2007-05-24 | N.V. Nutricia | Composition with docosapentaenoic acid |
| JP5658876B2 (ja) * | 2006-07-05 | 2015-01-28 | フォトンズ コーポレーション リミテッド | 大規模従属栄養培養領域にて産生される超高純度ｅｐａと極性脂質 |
| KR100684642B1 (ko) * | 2006-09-14 | 2007-02-22 | 주식회사 일신웰스 | 어유 유래 글리세라이드 유지 조성물 및 이의 제조방법 |
| CN102421422A (zh) * | 2009-03-09 | 2012-04-18 | 普罗诺瓦生物医药挪威公司 | 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途 |
| US20110071090A1 (en) * | 2009-03-11 | 2011-03-24 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle |
| US8241672B2 (en) * | 2009-03-11 | 2012-08-14 | Stable Solutions Llc | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions |
| MX377553B (es) | 2009-04-29 | 2025-03-10 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| BRPI1011883A2 (pt) * | 2009-06-15 | 2016-09-13 | Amarin Pharma Inc | uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina |
| JP2014505729A (ja) * | 2011-02-16 | 2014-03-06 | ピヴォタル セラピューティクス インコーポレイテッド | コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ） |
| JP2014505732A (ja) * | 2011-02-16 | 2014-03-06 | ピヴォタル セラピューティクス インコーポレイテッド | 心血管疾患において用いるための、スタチンおよびω３脂肪酸（ＥＰＡ、ＤＨＡおよびＤＰＡ） |
| WO2013192109A1 (en) * | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
-
2013
- 2013-12-06 KR KR1020157017202A patent/KR20150103009A/ko not_active Ceased
- 2013-12-06 CN CN202010984870.2A patent/CN112107570A/zh active Pending
- 2013-12-06 CN CN202110585483.6A patent/CN113274378A/zh active Pending
- 2013-12-06 CA CA2894366A patent/CA2894366A1/en not_active Abandoned
- 2013-12-06 JP JP2015545894A patent/JP6881893B2/ja not_active Expired - Fee Related
- 2013-12-06 MX MX2015007085A patent/MX2015007085A/es unknown
- 2013-12-06 EP EP13861394.8A patent/EP2929041A4/en not_active Withdrawn
- 2013-12-06 KR KR1020217013255A patent/KR20210059779A/ko not_active Abandoned
- 2013-12-06 AU AU2013354979A patent/AU2013354979A1/en not_active Abandoned
- 2013-12-06 CA CA2894183A patent/CA2894183A1/en not_active Abandoned
- 2013-12-06 CN CN201380063980.3A patent/CN104937103A/zh active Pending
- 2013-12-06 WO PCT/US2013/073701 patent/WO2014089501A1/en not_active Ceased
- 2013-12-06 EP EP13861305.4A patent/EP2928462A4/en not_active Withdrawn
- 2013-12-06 KR KR1020157016331A patent/KR20150103671A/ko not_active Ceased
- 2013-12-06 MX MX2015007082A patent/MX2015007082A/es unknown
- 2013-12-06 AU AU2013354969A patent/AU2013354969A1/en not_active Abandoned
- 2013-12-06 EP EP21170003.4A patent/EP3888646A1/en not_active Withdrawn
- 2013-12-06 WO PCT/US2013/073714 patent/WO2014089511A2/en not_active Ceased
- 2013-12-06 JP JP2015545896A patent/JP2016501249A/ja active Pending
- 2013-12-06 CN CN201380064003.5A patent/CN104902888A/zh active Pending
-
2015
- 2015-06-10 IN IN1505MU2015 patent/IN2015MU01505A/xx unknown
- 2015-06-10 IN IN5009DE2015 patent/IN2015DE05009A/xx unknown
-
2017
- 2017-09-22 AU AU2017232203A patent/AU2017232203A1/en not_active Abandoned
-
2018
- 2018-09-12 AU AU2018229440A patent/AU2018229440A1/en not_active Abandoned
-
2019
- 2019-06-20 JP JP2019114492A patent/JP2019172697A/ja active Pending
- 2019-08-14 AU AU2019216634A patent/AU2019216634A1/en not_active Abandoned
-
2020
- 2020-06-03 AU AU2020203658A patent/AU2020203658A1/en not_active Abandoned
-
2021
- 2021-03-24 AU AU2021201865A patent/AU2021201865A1/en not_active Abandoned
- 2021-05-19 JP JP2021084578A patent/JP2021120407A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170431A1 (es) | Lipido que comprende acido docosapentaenoico | |
| ES2666322T3 (es) | Composiciones farmacéuticas para el tratamiento de trastornos musculares | |
| MX2018003636A (es) | Composicion de uridina y citidina para su uso en la prevencion o tratamiento de neurotrauma. | |
| MX349678B (es) | Producción de ácidos grasos poliinsaturados de cadena larga en células vegetales. | |
| MX2014000770A (es) | Composiciones de acidos grasos. | |
| PE20231189A1 (es) | Acidos grasos poliinsaturados de cadena muy larga a partir de aceites naturales | |
| CO7121328A2 (es) | Composiciones de ester de ácido graso omega -3 | |
| BR112013020346A2 (pt) | concentrado de ácido eicosapentaenoico, produto farmac~eutico, método de elaboração de um concentrado de ácido eicosapentaenoico e uso de óleo microbiano | |
| EA201591680A1 (ru) | Смесь жирных кислот (гжк, группа жирных кислот) и её применение для лечения воспалительных патологий | |
| WO2014165190A3 (en) | Compositions comprising docosapentaenoic acid and methods of use | |
| GEP201606568B (en) | Compositions for the treatment of neurologic disorders | |
| CL2015001138A1 (es) | Retiro de componentes indeseados de las composiciones de aceite | |
| MX383445B (es) | Composiciones alimenticias para mascotas. | |
| BR112016025931A8 (pt) | composição de barra de sabão extrudada, barra e método para intensificar a transparência das barras de sabão | |
| WO2011097276A8 (en) | Methods and compositions for treating arthritis with docosahexaenoic acid | |
| BR112014010347A2 (pt) | óleo contendo ácido graxo poliinsaturado oxidativamente estável | |
| PL3784044T3 (pl) | Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha | |
| CL2016001453A1 (es) | Composiciones sintéticas de leche que comprenden ácidos grasos poliinsaturados (pufa) para promover el establecimiento saludable de la función cognitiva en infantes varones y hembras y niños y niñas. | |
| PL3809858T3 (pl) | Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha | |
| JP2016519101A5 (enExample) | ||
| PE20212373A1 (es) | Composiciones de acidos grasos poliinsaturados enriquecidos con dha | |
| PE20211482A1 (es) | Composiciones de acidos grasos poliinsaturados enriquecidos con dha | |
| PE20212374A1 (es) | Composiciones de acidos grasos poliinsaturados enriquecidos con dha | |
| BR112017008361A2 (pt) | método para aumentar o nível de ácidos graxos ômega-3 em gado bovino | |
| CO2017005911A2 (es) | Método para incrementar niveles de ácidos grasos de omega-3 en productos de carne de res por medio de administración de una dieta de pasto y algas |